All In Biotech

Drug Trial Radar · NCT07248956

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma

Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal Carcinoma: A Multicenter Randomized Controlled Study

Last checked: Nov 19, 2026Latest source record: Dec 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 116 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

116

Planned (sponsor's estimate)

Start

Dec 22, 2025

Primary completion

Nov 30, 2027

Study completion Dec 30, 2029

Sponsor

Lead sponsor
Eye & ENT Hospital of Fudan UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Nov 25, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized controlled, prospective clinical study.

Conditions

  • Hypopharyngeal Carcinoma

Interventions

  • FinolizumabDrug

    200mg every 3 weeks (q3w) for 2 cycles.

  • Albumin-Bound Paclitaxel /nab-PaclitaxelDrug

    260mg/m², day 1, every 3 weeks (q3w) for 2 cycles.

  • CisplatinDrug

    25mg/m², days 1-3, every 3 weeks (q3w) for 2 cycles.

  • Definitive radiotherapyRadiation

    Definitive radiotherapy (68-70Gy) with concurrent cisplatin-based chemotherapy (25mg/m², days 1-3, every 3 weeks)

  • Surgery with postoperative radiotherapy or chemoradiotherapy.Procedure

    surgery with postoperative radiotherapy or chemoradiotherapy.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survival (EFS)Time frame: 2 years

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing Tongren Hospital, Capital Medical University

    Beijing, China · Not yet recruiting

  • Cancer Hospital Chinese Academy of Medical Sciences

    Beijing, China · Not yet recruiting

  • Eye & ENT Hospital, Fudan University

    Shanghai, China · Recruiting

  • Zhongshan Hospital of Fudan University

    Shanghai, China · Not yet recruiting

  • Tianjin Medical University Cancer Institute & Hospital

    Tianjin, China · Not yet recruiting

  • Harbin Medical University Cancer Hospital

    Harbin, Heilongjiang, China · Not yet recruiting

  • Shandong Provincial ENT Hospital

    Jinan, Shandong, China · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.